Abelson tyrosine-protein kinase 1 as principal target for drug discovery against leukemias role of the current computer-aided drug design methodologies

Current Topics in Medicinal Chemistry

Volumn 12, Issue 24, 2012, Pages 2745-2762

  Speck Planche, Alejandro ^a   Luan, Feng ^a,b   Cordeiro, M ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b YANTAI UNIVERSITY   (China)

Author keywords

Artificial neural networks; Fragments; In silico design; Inhibitors; Kinase; Leukemias; Linear discriminant analysis; Molecular docking; QSAR; Quantitative contributions

Indexed keywords

ABELSON TYROSINE PROTEIN KINASE 1; ABELSON TYROSINE PROTEIN KINASE 1 INHIBITOR; BOSUTINIB; ERLOTINIB; GEFITINIB; IMATINIB; JANUS KINASE 2; NILOTINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PONATINIB; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; TUMOR PROTEIN;

ARTICLE; BIOLOGICAL ACTIVITY; CANCER INHIBITION; CHEMICAL STRUCTURE; COMPUTER AIDED DESIGN; COMPUTER MODEL; HIGH THROUGHPUT SCREENING; HUMAN; LEUKEMIA; MATHEMATICAL MODEL; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN CONFORMATION; PROTEIN PHOSPHORYLATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BINDING SITE; CHEMISTRY; CHILD; DRUG ANTAGONISM; DRUG DESIGN; MOLECULAR DOCKING; MOLECULAR LIBRARY; PROTEIN BINDING; REVIEW;

ANTINEOPLASTIC AGENTS; BINDING SITES; CHILD; COMPUTER-AIDED DESIGN; DRUG DESIGN; HUMANS; LEUKEMIA; MOLECULAR DOCKING SIMULATION; NEOPLASM PROTEINS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SMALL MOLECULE LIBRARIES;

EID: 84883689309     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611212240005     Document Type: Article

References (181)

1. Mughal, T.I.; Goldman, J.M.; Mughal, S.T. Understanding Leukemias, Lymphomas and Myelomas, Taylor & Francis Group: London, New York, 2006.
2. Heffner Jr, L.T. Epidemiology, risk factors and classification. In Clinical Malignant Hematology, Sekeres, M.A.; Kalaycio, M.E.; Bolwell, B.J., Eds. McGraw-Hill Companies, Inc.: New York, Chicago, San Francisco, Lisbon, London, Madrid, Mexico City, Milan, New Delhi, San Juan, Seoul, Singapore, Sydney, Toronto, 2007; pp 1-7.
3. Pinkel, D. Historical perspective. In Childhood Leukemias, 2nd ed.; Pui, C.H., Ed. Cambridge University Press: Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, São Paulo, 2006; pp 3-20.
4. Spector, L.G.; Ross, J.A.; Robison, L.L.; Bhatia, S. Epidemiology and etiology. In Childhood Leukemias, 2nd ed.; Pui, C.H., Ed. Cambridge University Press: Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, São Paulo, 2006; pp 48-66.
5. EBI-Team. ChEMBL Database. http://www.ebi.ac.uk/chembldb/,2010.
6. Kubinyi, H. QSAR: Hansch Analysis and Related Approaches, VCH Publishers: Weinheim, New York, Basel, Cambridge, Tokyo, 1993.
7. Gasteiger, J. Handbook of Chemoinformatics, WILEY-VCH Verlag GmbH & Co. KGaA: Weinheim, 2003.
8. Oprea, T. Chemoinformatics in Drug Discovery, WILEY-VCH Verlag GmbH & Co. KGaA: Weinheim, 2005.
9. Todeschini, R.; Consonni, V. Molecular Descriptors for Chemoinformatics, WILEY-VCH Verlag GmbH & Co. KGaA: Weinheim, 2009.
10. Larson, R.S. Bioinformatics and Drug Discovery, Humana Press Inc: Totowa, New Jersey, 2006.
11. Gonzalez-Diaz, H.; Munteanu, C.R. Topological Indices for Medicinal Chemistry, Biology, Parasitology, Neurological and Social Networks, Transworld Research Network: Kerala, 2010.
12. Doucet, J.P.; Weber, J. Computer-Aided Molecular Design: Theory and Applications, Academic Press: London, San Diego, New York, Boston, Sidney, Tokyo, Toronto, 1996.
13. Hamacher, M.; Marcus, K.; Stühler, K.; van Hall, A.; Warscheid, B.; Meyer, H.E. Proteomics in Drug Research, Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, 2006.
14. van de Waterbeemd, H. Advanced Computer-Assisted Techniques in Drug Discovery, VCH Publishers: Weinheim, New York, Basel, Cambridge, Tokyo, 1995.
15. Alvarez, J.; Shoichet, B. Virtual Screening in Drug Discovery, CRC Press. Taylor & Francis Group: Boca Raton, London, New York, Singapore, 2005.
16. Estrada, E. Structure-mutagenicity relationships in 2-furylethylene derivatives. A molecular orbital study of the role of nitro groups. Mutat. Res., 1998, 420, 67-75.
17. Estrada, E. On the topological sub-structural molecular design (TOSS-MODE) in QSPR/QSAR and drug design research. SAR QSAR Environ. Res., 2000, 11, 55-73.
18. Estrada, E. A computer-based approach to describe the 13C NMR chemical shifts of alkanes by the generalized spectral moments of iterated line graphs. Comput. Chem., 2000, 24, 193-201.
19. Estrada, E.; Delgado, E.J.; Alderete, J.B.; Jana, G.A. Quantum-connectivity descriptors in modeling solubility of environmentally important organic compounds. J. Comput. Chem., 2004, 25, 1787-1796
20. Estrada, E.; Molina, E. Automatic extraction of structural alerts for predicting chromosome aberrations of organic compounds. J. Mol. Graph. Model., 2006, 25, 275-288.
21. Fernandez, M.; Tundidor-Camba, A.; Caballero, J. Modeling of cyclin-dependent kinase inhibition by 1H-pyrazolo[3,4- d]pyrimidine derivatives using artificial neural network ensembles. J. Chem. Inf. Model., 2005, 45, 1884-1895.
22. Gonzalez, M.P.; Caballero, J.; Helguera, A.M.; Garriga, M.; Gonzalez, G.; Fernandez, M. 2D autocorrelation modelling of the inhibitory activity of cytokinin-derived cyclin-dependent kinase inhibitors. Bull. Math. Biol., 2006, 68, 735-751.
23. Caballero, J.; Fernandez, M. Linear and nonlinear modeling of antifungal activity of some heterocyclic ring derivatives using multiple linear regression and Bayesian-regularized neural networks. J. Mol. Model., 2006, 12, 168-181.
24. de Cerqueira Lima, P.; Golbraikh, A.; Oloff, S.; Xiao, Y.; Tropsha, A. Combinatorial QSAR modeling of P-glycoprotein substrates. J. Chem. Inf. Model., 2006, 46, 1245-1254.
25. Friedel, C.C.; Jahn, K.H.; Sommer, S.; Rudd, S.; Mewes, H.W.; Tetko, I.V. Support vector machines for separation of mixed plant- pathogen EST collections based on codon usage. Bioinformatics, 2005, 21, 1383-1388.
26. Goodarzi, M.; Duchowicz, P.R.; Wu, C.H.; Fernandez, F.M.; Castro, E.A. New hybrid genetic based Support Vector Regression as QSAR approach for analyzing flavonoids-GABA(A) complexes. J. Chem. Inf. Model., 2009, 49, 1475-1485
27. Li, Q.; Jorgensen, F.S.; Oprea, T.; Brunak, S.; Taboureau, O. hERG classification model based on a combination of support vector machine method and GRIND descriptors. Mol. Pharm., 2008, 5, 117-127.
28. Votano, J.R.; Parham, M.; Hall, L.M.; Hall, L.H.; Kier, L.B.; Oloff, S.; Tropsha, A. QSAR modeling of human serum protein binding with several modeling techniques utilizing structure-information representation. J. Med. Chem., 2006, 49, 7169-7181.
29. Roy, K.; Mandal, A.S. Predictive QSAR modeling of CCR5 antagonist piperidine derivatives using chemometric tools. J. Enzyme Inhib. Med. Chem., 2009, 24, 205-223.
30. Scotti, M.T.; Fernandes, M.B.; Ferreira, M.J.; Emerenciano, V.P. Quantitative structure-activity relationship of sesquiterpene lactones with cytotoxic activity. Bioorg. Med. Chem., 2007, 15, 2927-2934.
31. Cao, H.; Cao, R.; Zhang, H.; Zheng, X.; Gao, D. Non-nucleoside inhibitors of NS5B polymerase binding to allosteric sites: 3D-QSAR and molecular docking studies. Curr. Med. Chem., 2008, 15, 1462-1477.
32. Estrada, E.; Uriarte, E.; Molina, E.; Simon-Manso, Y.; Milne, G.W. An integrated in silico analysis of drug-binding to human serum albumin. J. Chem. Inf. Model., 2006, 46, 2709-2724.
33. Estrada, E.; Quincoces, J.A.; Patlewicz, G. Creating molecular diversity from antioxidants in Brazilian propolis. Combination of TOPS-MODE QSAR and virtual structure generation. Mol. Divers., 2004, 8, 21-33.
34. Estrada, E.; Uriarte, E.; Montero, A.; Teijeira, M.; Santana, L.; De Clercq, E. A novel approach for the virtual screening and rational design of anticancer compounds. J. Med. Chem., 2000, 43, 1975-1985.
35. Estrada, E.; Peña, A. In silico studies for the rational discovery of anticonvulsant compounds. Bioorg. Med. Chem., 2000, 8, 2755-2770
36. Speck-Planche, A.; Luan, F.; Cordeiro, M.N.D.S. Discovery of anti-Alzheimer agents: current ligand-based approaches toward the design of acetylcholinesterase inhibitors. Mini Rev. Med. Chem., 2012, 12, 583-591
37. Speck-Planche, A.; Cordeiro, M.N.D.S. Computer-aided drug design methodologies toward the design of anti-hepatitis C agents. Curr. Top. Med. Chem., 2012, 12, 802-813.
38. Speck-Planche, A.; Guilarte-Montero, L.; Yera-Bueno, R.; Rojas-Vargas, J.A.; Garcia-Lopez, A.; Uriarte, E.; Molina-Perez, E. Rational design of new agrochemical fungicides using substructural descriptors. Pest Manag. Sci., 2011, 67, 438-445
39. Speck-Planche, A.; Cordeiro, M.N.D.S.; Guilarte-Montero, L.; Yera-Bueno, R. Current computational approaches towards the rational design of new insecticidal agents. Curr. Comput. Aided Drug Des., 2011, 7, 304-314
40. Speck-Planche, A.; Cordeiro, M.N.D.S. Current drug design of anti-HIV agents through the inhibition of C-C chemokine receptor type 5. Curr. Comput. Aided Drug Des., 2011, 7, 238-248.
41. Speck-Planche, A.; Scotti, M.T.; Emerenciano, V.P.; García-López, A.; Molina-Pérez, E.; Uriarte, E. Designing novel antitrypanosomal agents from a mixed graph-theoretical substructural approach. J. Comput. Chem., 2010, 31, 882-894
42. Speck-Planche, A.; Scotti, M.T.; de Paulo-Emerenciano, V. Current pharmaceutical design of antituberculosis drugs: future perspectives. Curr. Pharm. Des., 2010, 16, 2656-2665.
43. Speck-Planche, A.; Scotti, M.T.; García-López, A.; Emerenciano, V.P.; Molina-Pérez, E.; Uriarte, E. Design of novel antituberculosis compounds using graph-theoretical and substructural approaches. Mol. Divers., 2009, 13, 445-458.
44. Vilar, S.; Gonzalez-Diaz, H.; Santana, L.; Uriarte, E. A network-QSAR model for prediction of genetic-component biomarkers in human colorectal cancer. J. Theor. Biol., 2009, 261, 449-458.
45. Garcia, I.; Munteanu, C.R.; Fall, Y.; Gomez, G.; Uriarte, E.; Gonzalez-Diaz, H. QSAR and complex network study of the chiral HMGR inhibitor structural diversity. Bioorg. Med. Chem., 2009, 17, 165-175.
46. Santana, L.; Gonzalez-Diaz, H.; Quezada, E.; Uriarte, E.; Yanez, M.; Vina, D.; Orallo, F. Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J. Med. Chem., 2008, 51, 6740-6751.
47. Gonzalez-Diaz, H.; Bonet, I.; Teran, C.; De Clercq, E.; Bello, R.; Garcia, M.M.; Santana, L.; Uriarte, E. ANN-QSAR model for selection of anticancer leads from structurally heterogeneous series of compounds. Eur. J. Med. Chem., 2007, 42, 580-585.
48. Santana, L.; Uriarte, E.; Gonzalez-Diaz, H.; Zagotto, G.; Soto-Otero, R.; Mendez-Alvarez, E. A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins. J. Med. Chem., 2006, 49, 1149-1156.
49. Gonzalez-Diaz, H.; Vina, D.; Santana, L.; de Clercq, E.; Uriarte, E. Stochastic entropy QSAR for the in silico discovery of anticancer compounds: prediction, synthesis, and in vitro assay of new purine carbanucleosides. Bioorg. Med. Chem., 2006, 14, 1095-1107.
50. Gonzalez-Diaz, H.; Torres-Gomez, L.A.; Guevara, Y.; Almeida, M.S.; Molina, R.; Castanedo, N.; Santana, L.; Uriarte, E. Markovian chemicals "in silico" design (MARCH-INSIDE), a promising approach for computer-aided molecular design III: 2.5D indices for the discovery of antibacterials. J. Mol. Model., 2005, 11, 116-123.
51. Gonzalez-Diaz, H.; Cruz-Monteagudo, M.; Vina, D.; Santana, L.; Uriarte, E.; De Clercq, E. QSAR for anti-RNA-virus activity, synthesis, and assay of anti-RSV carbonucleosides given a unified representation of spectral moments, quadratic, and topologic indices. Bioorg. Med. Chem. Lett., 2005, 15, 1651-1657.
52. Gonzalez-Diaz, H.; Aguero-Chapin, G.; Varona-Santos, J.; Molina, R.; de la Riva, G.; Uriarte, E. 2D RNA-QSAR: assigning ACC oxidase family membership with stochastic molecular descriptors; isolation and prediction of a sequence from Psidium guajava L. Bioorg. Med. Chem. Lett., 2005, 15, 2932-2937.
53. Vega, M.C.; Rolon, M.; Montero-Torres, A.; Fonseca-Berzal, C.; Escario, J.A.; Gomez-Barrio, A.; Galvez, J.; Marrero-Ponce, Y.; Aran, V.J. Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5- nitroindazolinones, new prototypes of antichagasic drug. Eur. J. Med. Chem., 2012, 58C, 214-227.
54. Castillo-Garit, J.A.; Del Toro-Cortes, O.; Kouznetsov, V.V.; Puentes, C.O.; Romero Bohorquez, A.R.; Vega, M.C.; Rolon, M.; Escario, J.A.; Gomez-Barrio, A.; Marrero-Ponce, Y.; Torrens, F.; Abad, C. Identification in silico and in vitro of novel trypanosomicidal drug-like compounds. Chem. Biol. Drug Des., 2012, 80, 38-45.
55. Marrero-Ponce, Y.; Siverio-Mota, D.; Galvez-Llompart, M.; Recio, M.C.; Giner, R.M.; Garcia-Domenech, R.; Torrens, F.; Aran, V.J.; Cordero-Maldonado, M.L.; Esguera, C.V.; de Witte, P.A.; Crawford, A.D. Discovery of novel anti-inflammatory drug-like compounds by aligning in silico and in vivo screening: the nitroindazolinone chemotype. Eur. J. Med. Chem., 2011, 46, 5736-5753.
56. Casañola-Martin, G.M.; Marrero-Ponce, Y.; Khan, M.T.; Khan, S.B.; Torrens, F.; Perez-Jimenez, F.; Rescigno, A.; Abad, C. Bond- based 2D quadratic fingerprints in QSAR studies: virtual and in vitro tyrosinase inhibitory activity elucidation. Chem. Biol. Drug Des., 2010, 76, 538-545.
57. Marrero-Ponce, Y.; Meneses-Marcel, A.; Rivera-Borroto, O.M.; Garcia-Domenech, R.; De Julian-Ortiz, J.V.; Montero, A.; Escario, J.A.; Barrio, A.G.; Pereira, D.M.; Nogal, J.J.; Grau, R.; Torrens, F.; Vogel, C.; Aran, V.J. Bond-based linear indices in QSAR: computational discovery of novel anti-trichomonal compounds. J. Comput. Aided Mol. Des., 2008, 22, 523-540
58. Casanola-Martin, G.M.; Marrero-Ponce, Y.; Tareq Hassan Khan, M.; Torrens, F.; Perez-Gimenez, F.; Rescigno, A. Atom- and bond-based 2D TOMOCOMD-CARDD approach and ligand-based virtual screening for the drug discovery of new tyrosinase inhibitors. J. Biomol. Screen., 2008, 13, 1014-1024
59. Castillo-Garit, J.A.; Marrero-Ponce, Y.; Torrens, F.; Rotondo, R. Atom-based stochastic and non-stochastic 3D-chiral bilinear indices and their applications to central chirality codification. J. Mol. Graph. Model., 2007, 26, 32-47
60. Tenorio-Borroto, E.; Penuelas Rivas, C.G.; Vasquez Chagoyan, J.C.; Castanedo, N.; Prado-Prado, F.J.; Garcia-Mera, X.; Gonzalez- Diaz, H. ANN multiplexing model of drugs effect on macrophages; theoretical and flow cytometry study on the cytotoxicity of the anti-microbial drug G1 in spleen. Bioorg. Med. Chem., 2012, 20, 6181-6194
61. Garcia, I.; Fall, Y.; Gomez, G.; Gonzalez-Diaz, H. First computational chemistry multi-target model for anti-Alzheimer, anti-parasitic, anti-fungi, and anti-bacterial activity of GSK-3 inhibitors in vitro, in vivo, and in different cellular lines. Mol. Divers., 2011, 15, 561-567
62. Prado-Prado, F.J.; Garcia-Mera, X.; Gonzalez-Diaz, H. Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorg. Med. Chem., 2010, 18, 2225-2231
63. Vina, D.; Uriarte, E.; Orallo, F.; Gonzalez-Diaz, H. Alignment-free prediction of a drug-target complex network based on parameters of drug connectivity and protein sequence of receptors. Mol. Pharm., 2009, 6, 825-835
64. Prado-Prado, F.J.; Uriarte, E.; Borges, F.; Gonzalez-Diaz, H. Multi- target spectral moments for QSAR and Complex Networks study of antibacterial drugs. Eur. J. Med. Chem., 2009, 44, 4516-4521
65. Prado-Prado, F.J.; Martinez de la Vega, O.; Uriarte, E.; Ubeira, F.M.; Chou, K.C.; Gonzalez-Diaz, H. Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Bioorg. Med. Chem., 2009, 17, 569-575
66. Prado-Prado, F.J.; Borges, F.; Uriarte, E.; Perez-Montoto, L.G.; Gonzalez-Diaz, H. Multi-target spectral moment: QSAR for antiviral drugs vs. different viral species. Anal. Chim. Acta, 2009, 651, 159-164
67. Perez-Montoto, L.G.; Santana, L.; Gonzalez-Diaz, H. Scoring function for DNA-drug docking of anticancer and antiparasitic compounds based on spectral moments of 2D lattice graphs for molecular dynamics trajectories. Eur. J. Med. Chem., 2009, 44, 4461-4469
68. Munteanu, C.R.; Magalhaes, A.L.; Uriarte, E.; Gonzalez-Diaz, H. Multi-target QPDR classification model for human breast and colon cancer-related proteins using star graph topological indices. J. Theor. Biol., 2009, 257, 303-311.
69. Speck-Planche, A.; Luan, F.; Cordeiro, M.N.D.S. Role of ligand-based drug design methodologies toward the discovery of new anti- Alzheimer agents: futures perspectives in Fragment-Based Ligand Design. Curr. Med. Chem., 2012, 19, 1635-1645
70. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N.D.S. Chemoinformatics in multi-target drug discovery for anti-cancer therapy: in silico design of potent and versatile anti- brain tumor agents. Anticancer Agents Med. Chem., 2012, 12, 678-685
71. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N.D.S. In silico discovery and virtual screening of multi-target inhibitors for proteins in Mycobacterium tuberculosis. Comb. Chem. High Throughput Screen., 2012, 15, 666-673
72. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N.D.S. Predicting multiple ecotoxicological profiles in agrochemical fungicides: a multi-species chemoinformatic approach. Ecotoxicol. Environ. Saf., 2012, 80, 308-313
73. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N.D.S. Chemoinformatics in anti-cancer chemotherapy: multi- target QSAR model for the in silico discovery of anti-breast cancer agents. Eur. J. Pharm. Sci., 2012, 47, 273-279
74. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N.D.S. A ligand-based approach for the in silico discovery of multi-target inhibitors for proteins associated with HIV infection. Mol. Biosyst., 2012, 8, 2188-2196
75. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N.D.S. Rational drug design for anti-cancer chemotherapy: multi-target QSAR models for the in silico discovery of anti- colorectal cancer agents. Bioorg. Med. Chem., 2012, 20, 4848-4855
76. Speck-Planche, A.; Kleandrova, V.V. In silico design of multi- target inhibitors for C-C chemokine receptors using substructural descriptors. Mol. Divers., 2012, 16, 183-191
77. Molina, E.; Sobarzo-Sanchez, E.; Speck-Planche, A.; Matos, M.J.; Uriarte, E.; Santana, L.; Yanez, M.; Orallo, F. Monoamino oxidase a: an interesting pharmacological target for the development of multi-target QSAR. Mini Rev. Med. Chem., 2012, 12, 947-958
78. Speck-Planche, A.; Kleandrova, V.V.; Rojas-Vargas, J.A. QSAR model toward the rational design of new agrochemical fungicides with a defined resistance risk using substructural descriptors. Mol. Divers., 2011, 15, 901-909
79. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N.D.S. Multi-target drug discovery in anti-cancer therapy: fragment-based approach toward the design of potent and versatile anti-prostate cancer agents. Bioorg. Med. Chem., 2011, 19, 6239-6244
80. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N.D.S. Fragment-based QSAR model toward the selection of versatile anti-sarcoma leads. Eur. J. Med. Chem., 2011, 46, 5910-5916
81. Speck-Planche, A.; Cordeiro, M.N.D.S. Application of Bioinformatics for the search of novel anti-viral therapies: Rational design of anti-herpes agents. Curr. Bioinform., 2011, 6, 81-93.
82. Gonzalez-Diaz, H.; Prado-Prado, F.; Sobarzo-Sanchez, E.; Haddad, M.; Maurel Chevalley, S.; Valentin, A.; Quetin-Leclercq, J.; Dea- Ayuela, M.A.; Teresa Gomez-Munos, M.; Munteanu, C.R.; Jose Torres-Labandeira, J.; Garcia-Mera, X.; Tapia, R.A.; Ubeira, F.M. NL MIND-BEST: A web server for ligands and proteins discovery- Theoretic-experimental study of proteins of Giardia lamblia and new compounds active against Plasmodium falciparum. J. Theor. Biol., 2011, 276, 229-249
83. Gonzalez-Diaz, H.; Prado-Prado, F.; Garcia-Mera, X.; Alonso, N.; Abeijon, P.; Caamano, O.; Yanez, M.; Munteanu, C.R.; Pazos, A.; Dea-Ayuela, M.A.; Gomez-Munoz, M.T.; Garijo, M.M.; Sansano, J.; Ubeira, F.M. MIND-BEST: Web Server for Drugs and Target Discovery; Design, Synthesis, and Assay of MAO-B Inhibitors and Theoretical-Experimental Study of G3PDH Protein from Trichomonas gallinae. J. Proteome Res., 2011, 10, 1698-1718
84. Gonzalez-Diaz, H.; Muino, L.; Anadon, A.M.; Romaris, F.; Prado-Prado, F.J.; Munteanu, C.R.; Dorado, J.; Sierra, A.P.; Mezo, M.; Gonzalez-Warleta, M.; Garate, T.; Ubeira, F.M. MISS-Prot: web server for self/non-self discrimination of protein residue networks in parasites; theory and experiments in Fasciola peptides and Anisakis allergens. Mol. Biosyst., 2011.
85. Gonzalez-Diaz, H.; Riera-Fernandez, P. New Markov-Autocorrelation Indices for Re-evaluation of Links in Chemical and Biological Complex Networks used in Metabolomics, Parasitology, Neurosciences, and Epidemiology. J. Chem. Inf. Model., 2012.
86. Prado-Prado, F.; Garcia-Mera, X.; Abeijon, P.; Alonso, N.; Caamano, O.; Yanez, M.; Garate, T.; Mezo, M.; Gonzalez-Warleta, M.; Muino, L.; Ubeira, F.M.; Gonzalez-Diaz, H. Using entropy of drug and protein graphs to predict FDA drug-target network: theoretic-experimental study of MAO inhibitors and hemoglobin peptides from Fasciola hepatica. Eur. J. Med. Chem., 2011, 46, 1074-1094.
87. Prado-Prado, F.J.; Ubeira, F.M.; Borges, F.; Gonzalez-Diaz, H. Unified QSAR & network-based computational chemistry approach to antimicrobials. II. Multiple distance and triadic census analysis of antiparasitic drugs complex networks. J. Comput. Chem., 2009, 31, 164-173.
88. Munteanu, C.R.; Vazquez, J.M.; Dorado, J.; Sierra, A.P.; Sanchez-Gonzalez, A.; Prado-Prado, F.J.; Gonzalez-Diaz, H. Complex network spectral moments for ATCUN motif DNA cleavage: first predictive study on proteins of human pathogen parasites. J. Proteome Res., 2009, 8, 5219-5228.
89. Gonzalez-Diaz, H.; Prado-Prado, F.J. Unified QSAR and network-based computational chemistry approach to antimicrobials, part 1: multispecies activity models for antifungals. J. Comput. Chem., 2008, 29, 656-667.
90. Estrada, E. Generalized walks-based centrality measures for complex biological networks. J. Theor. Biol., 2010, 263, 556-565.
91. Estrada, E. Universality in protein residue networks. Biophys J, 2010, 98, 890-900.
92. Estrada, E. Information mobility in complex networks. Phys. Rev. E Stat. Nonlin. Soft Matter Phys., 2009, 80, 026104
93. Estrada, E.; Bodin, O. Using network centrality measures to manage landscape connectivity. Ecol Appl, 2008, 18, 1810-1825.
94. Estrada, E. Topological structural classes of complex networks. Phys. Rev. E Stat. Nonlin. Soft Matter Phys., 2007, 75, 016103
95. Riera-Fernandez, P.; Martin-Romalde, R.; Prado-Prado, F.J.; Escobar, M.; Munteanu, C.R.; Concu, R.; Duardo-Sanchez, A.; Gonzalez-Diaz, H. From QSAR models of drugs to complex networks: state-of-art review and introduction of new Markov- spectral moments indices. Curr. Top. Med. Chem., 2012, 12, 927-960
96. Chan, L.W.; Wang, F.F.; Cho, W.C. Genomic sequence analysis of EGFR regulation by microRNAs in lung cancer. Curr. Top. Med. Chem., 2012, 12, 920-926.
97. Garcia, I.; Fall, Y.; Gomez, G. Review of synthesis, biological assay, and QSAR studies of HMGR inhibitors. Curr. Top. Med. Chem., 2012, 12, 895-919.
98. Luan, F.; Borges, F.; Cordeiro, M.N.D.S. Recent advances on A(3) adenosine receptor antagonists by QSAR tools. Curr. Top. Med. Chem., 2012, 12, 878-894.
99. Moura Barbosa, A.J.; Del Rio, A. Freely accessible databases of commercial compounds for high- throughput virtual screenings. Curr. Top. Med. Chem., 2012, 12, 866-877.
100. Castillo-Garit, J.A.; Abad, C.; Rodriguez-Borges, J.E.; Marrero- Ponce, Y.; Torrens, F. A eview of QSAR studies to discover new drug-like compounds actives against leishmaniasis and trypanosomiasis. Curr. Top. Med. Chem., 2012, 12, 852-865.
101. Dave, K.; Lahiry, A. Conotoxins: review and docking studies to determine potentials of conotoxin as an anticancer drug molecule. Curr. Top. Med. Chem., 2012, 12, 845-851
102. Nino, H.; Rodriguez-Borges, J.E.; Garcia-Mera, X.; Prado-Prado, F. Review of synthesis, assay, and prediction of beta and gamma-secretase inhibitors. Curr. Top. Med. Chem., 2012, 12, 828-844
103. Khan, M.T.; Mischiati, C.; Ather, A.; Ohyama, T.; Dedachi, K.; Borgatti, M.; Kurita, N.; Gambari, R. Structure-based analysis of the molecular recognitions between HIV-1 TAR-RNA and transcription factor nuclear factor-kappaB (NFkB). Curr. Top. Med. Chem., 2012, 12, 814-827
104. Gonzalez-Diaz, H. Editorial: QSAR/QSPR models as enabling technologies for drug & targets discovery in: medicinal chemistry, microbiology-parasitology, neurosciences, bioinformatics, proteomics and other biomedical sciences. Curr. Top. Med. Chem., 2012, 12, 799-801
105. Speck-Planche, A.; Kleandrova, V.V. QSAR and molecular docking techniques for the discovery of potent monoamine oxidase B inhibitors: Computer-aided generation of new rasagiline bioisosteres. Curr. Top. Med. Chem., 2012, 12, 1734-1747
106. Vazquez-Naya, J.M.; Martinez-Romero, M.; Porto-Pazos, A.B.; Novoa, F.; Valladares-Ayerbes, M.; Pereira, J.; Munteanu, C.R.; Dorado, J. Ontologies of drug discovery and design for neurology, cardiology and oncology. Curr. Pharm. Des., 2010, 16, 2724-2736
107. Roy, K.; Ghosh, G. Exploring QSARs with Extended Topochemical Atom (ETA) indices for modeling chemical and drug toxicity. Curr. Pharm. Des., 2010, 16, 2625-2639
108. Munteanu, C.R.; Fernandez-Blanco, E.; Seoane, J.A.; Izquierdo- Novo, P.; Rodriguez-Fernandez, J.A.; Prieto-Gonzalez, J.M.; Rabunal, J.R.; Pazos, A. Drug discovery and design for complex diseases through QSAR computational methods. Curr. Pharm. Des., 2010, 16, 2640-2655
109. Marrero-Ponce, Y.; Casanola-Martin, G.M.; Khan, M.T.; Torrens, F.; Rescigno, A.; Abad, C. Ligand-based computer-aided discovery of tyrosinase inhibitors. Applications of the TOMOCOMD-CARDD method to the elucidation of new compounds. Curr. Pharm. Des., 2010, 16, 2601-2624
110. Gonzalez-Diaz, H.; Romaris, F.; Duardo-Sanchez, A.; Perez- Montoto, L.G.; Prado-Prado, F.; Patlewicz, G.; Ubeira, F.M. Predicting drugs and proteins in parasite infections with topological indices of complex networks: theoretical backgrounds, applications, and legal issues. Curr. Pharm. Des., 2010, 16, 2737-2764
111. Gonzalez-Diaz, H. QSAR and complex networks in pharmaceutical design, microbiology, parasitology, toxicology, cancer, and neurosciences. Curr. Pharm. Des., 2010, 16, 2598-2600.
112. Garcia, I.; Fall, Y.; Gomez, G. QSAR, docking, and CoMFA studies of GSK3 inhibitors. Curr. Pharm. Des., 2010, 16, 2666-2675
113. Galdeano, C.; Viayna, E.; Arroyo, P.; Bidon-Chanal, A.; Blas, J.R.; Munoz-Torrero, D.; Luque, F.J. Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents. Curr. Pharm. Des., 2010, 16, 2818-2836
114. Estrada, E.; Molina, E.; Nodarse, D.; Uriarte, E. Structural contributions of substrates to their binding to P-Glycoprotein. A TOPS-MODE approach. Curr. Pharm. Des., 2010, 16, 2676-2709
115. Concu, R.; Podda, G.; Ubeira, F.M.; Gonzalez-Diaz, H. Review of QSAR models for enzyme classes of drug targets: Theoretical background and applications in parasites, hosts, and other organisms. Curr. Pharm. Des., 2010, 16, 2710-2723
116. Chou, K.C. Graphic rule for drug metabolism systems. Curr. Drug Metab., 2010, 11, 369-378
117. Garcia, I.; Diop, Y.F.; Gomez, G. QSAR & complex network study of the HMGR inhibitors structural diversity. Curr. Drug Metab., 2010, 11, 307-314
118. Gonzalez-Diaz, H. Network topological indices, drug metabolism, and distribution. Curr. Drug Metab., 2010, 11, 283-284
119. Gonzalez-Diaz, H.; Duardo-Sanchez, A.; Ubeira, F.M.; Prado-Prado, F.; Perez-Montoto, L.G.; Concu, R.; Podda, G.; Shen, B. Review of MARCH-INSIDE & complex networks prediction of drugs: ADMET, anti-parasite activity, metabolizing enzymes and cardiotoxicity proteome biomarkers. Curr. Drug Metab., 2010, 11, 379-406
120. Khan, M.T. Predictions of the ADMET properties of candidate drug molecules utilizing different QSAR/QSPR modelling approaches. Curr. Drug Metab., 2010, 11, 285-295
121. Martinez-Romero, M.; Vazquez-Naya, J.M.; Rabunal, J.R.; Pita-Fernandez, S.; Macenlle, R.; Castro-Alvarino, J.; Lopez-Roses, L.; Ulla, J.L.; Martinez-Calvo, A.V.; Vazquez, S.; Pereira, J.; Porto- Pazos, A.B.; Dorado, J.; Pazos, A.; Munteanu, C.R. Artificial intelligence techniques for colorectal cancer drug metabolism: ontology and complex network. Curr. Drug Metab., 2010, 11, 347-368
122. Mrabet, Y.; Semmar, N. Mathematical methods to analysis of topology, functional variability and evolution of metabolic systems based on different decomposition concepts. Curr. Drug Metab., 2010, 11, 315-341
123. Wang, J.F.; Chou, K.C. Molecular modeling of cytochrome P450 and drug metabolism. Curr. Drug Metab., 2010, 11, 342-346
124. Zhong, W.Z.; Zhan, J.; Kang, P.; Yamazaki, S. Gender specific drug metabolism of PF-02341066 in rats--role of sulfoconjugation. Curr. Drug Metab., 2010, 11, 296-306.
125. Estrada, E. Virtual identification of essential proteins within the protein interaction network of yeast. Proteomics, 2006, 6, 35-40
126. Gonzalez-Diaz, H.; Gonzalez-Diaz, Y.; Santana, L.; Ubeira, F.M.; Uriarte, E. Proteomics, networks and connectivity indices. Proteomics, 2008, 8, 750-778
127. Torrens, F.; Castellano, G. Topological Charge-Transfer Indices: From Small Molecules to Proteins. Curr. Proteomics, 2009, 6, 204-213
128. Gonzalez-Diaz, H.; Prado-Prado, F.; Perez-Montoto, L.G.; Duardo-Sanchez, A.; Lopez-Diaz, A. QSAR Models for Proteins of Parasitic Organisms, Plants and Human Guests: Theory, Applications, Legal Protection, Taxes, and Regulatory Issues. Curr. Proteomics, 2009, 6, 214-227
129. Chen, J.; Shen, B. Computational Analysis of Amino Acid Mutation: A Proteome Wide Perspective. Curr. Proteomics, 2009, 6, 228-234.
130. Giuliani, A.; Di Paola, L.; Setola, R. Proteins as Networks: A Mesoscopic Approach Using Haemoglobin Molecule as Case Study. Curr. Proteomics, 2009, 6, 235-245.
131. Perez-Montoto, L.G.; Prado-Prado, F.; Ubeira, F.M.; Gonzalez-Diaz, H. Study of Parasitic Infections, Cancer, and other Diseases with Mass-Spectrometry and Quantitative Proteome-Disease Relationships. Curr. Proteomics, 2009, 6, 246-261.
132. Chou, K.C. Pseudo Amino Acid Composition and its Applications in Bioinformatics, Proteomics and System Biology. Curr. Proteomics, 2009, 6, 262-274.
133. Vazquez, J.M.; Aguiar, V.; Seoane, J.A.; Freire, A.; Serantes, J.A.; Dorado, J.; Pazos, A.; Munteanu, C.R. Star Graphs of Protein Sequences and Proteome Mass Spectra in Cancer Prediction. Curr. Proteomics, 2009, 6, 275-288
134. Ivanciuc, O. Machine Learning Quantitative Structure-Activity Relationships (QSAR) for Peptides Binding to the Human Amphiphysin-1 SH3 Domain. Curr. Proteomics, 2009, 6, 289-302.
135. Apweiler, R.; Wu, C.; Xenarios, I. UniProtKB. http://www.uniprot.org/,2002-2012.
136. Zhao, X.; Ghaffari, S.; Lodish, H.; Malashkevich, V.N.; Kim, P.S. Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat. Struct. Biol., 2002, 9, 117-120.
137. Mandal, S.; Moudgil, M.; Mandal, S. Rational drug design. Eur. J. Pharmacol., 2009, 625, 90-100.
138. Manley, P.W.; Cowan-Jacob, S.W.; Buchdunger, E.; Fabbro, D.; Fendrich, G.; Furet, P.; Meyer, T.; Zimmermann, J. Imatinib: a selective tyrosine kinase inhibitor. Eur. J. Cancer, 2002, 38, S19- S27.
139. Manley, P.W.; Stiefl, N.; Cowan-Jacob, S.W.; Kaufman, S.; Mestan, J.; Wartmann, M.; Wiesmann, M.; Woodman, R.; Gallagher, N. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg. Med. Chem., 2010, 18, 6977-6986.
140. Huang, W.S.; Metcalf, C.A.; Sundaramoorthi, R.; Wang, Y.; Zou, D.; Thomas, R.M.; Zhu, X.; Cai, L.; Wen, D.; Liu, S.; Romero, J.; Qi, J.; Chen, I.; Banda, G.; Lentini, S.P.; Das, S.; Xu, Q.; Keats, J.; Wang, F.; Wardwell, S.; Ning, Y.; Snodgrass, J.T.; Broudy, M.I.; Russian, K.; Zhou, T.; Commodore, L.; Narasimhan, N.I.; Mohemmad, Q.K.; Luliucci, J.; Rivera, V.M.; Dalgarno, D.C.; Sawyer, T.K.; Clackson, T.; Shakespeare, W.C. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR- ABL) kinase including the T315I gatekeeper mutant. J. Med. Chem., 2010, 53, 4701-4719.
141. Thaimattam, R.; Daga, P.R.; Banerjee, R.; Iqbal, J. 3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases. Bioorg. Med. Chem., 2005, 13, 4704-4712.
142. Manetti, F.; Brullo, C.; Magnani, M.; Mosci, F.; Chelli, B.; Crespan, E.; Schenone, S.; Naldini, A.; Bruno, O.; Trincavelli, M.L.; Maga, G.; Carraro, F.; Martini, C.; Bondavalli, F.; Botta, M. Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. J. Med. Chem., 2008, 51, 1252-1259.
143. Radi, M.; Crespan, E.; Botta, G.; Falchi, F.; Maga, G.; Manetti, F.; Corradi, V.; Mancini, M.; Santucci, M.A.; Schenone, S.; Botta, M. Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents. Bioorg. Med. Chem. Lett., 2008, 18, 1207-1211.
144. Schenone, S.; Brullo, C.; Bruno, O.; Bondavalli, F.; Mosti, L.; Maga, G.; Crespan, E.; Carraro, F.; Manetti, F.; Tintori, C.; Botta, M. Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines. Eur. J. Med. Chem., 2008, 43, 2665-2676.
145. Falchi, F.; Manetti, F.; Carraro, F.; Naldini, A.; Maga, G.; Crespan, E.; Schenone, S.; Bruno, O.; Brullo, C.; Botta, M. 3D QSAR models built on structure-based alignments of Abl tyrosine kinase inhibitors. ChemMedChem, 2009, 4, 976-987.
146. Santucci, M.A.; Corradi, V.; Mancini, M.; Manetti, F.; Radi, M.; Schenone, S.; Botta, M. C6-unsubstituted pyrazolo[3,4- d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines. ChemMedChem, 2009, 4, 118-126.
147. Liu, X.H.; Ma, X.H.; Tan, C.Y.; Jiang, Y.Y.; Go, M.L.; Low, B.C.; Chen, Y.Z. Virtual screening of Abl inhibitors from large compound libraries by support vector machines. J. Chem. Inf. Model., 2009, 49, 2101-2110.
148. Xu, F.; Shi, X.; Li, S.; Cui, J.; Lu, Z.; Jin, Y.; Lin, Y.; Pang, J.; Pan, J. Design, synthesis, and biological evaluation of novel water- soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl. Bioorg. Med. Chem., 2010, 18, 1806-1815.
149. Zhang, C.; Tan, C.; Zu, X.; Zhai, X.; Liu, F.; Chu, B.; Ma, X.; Chen, Y.; Gong, P.; Jiang, Y. Exploration of (S)-3- aminopyrrolidine as a potentially interesting scaffold for discovery of novel Abl and PI3K dual inhibitors. Eur. J. Med. Chem., 2011, 46, 1404-1414
150. Lu, S.; Luo, Q.; Hao, X.; Li, X.; Ji, L.; Zheng, W.; Wang, F. Synthesis and docking study of 2-phenylaminopyrimidine Abl tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett., 2011, 21, 6964-6968.
151. Marzaro, G.; Chilin, A.; Guiotto, A.; Uriarte, E.; Brun, P.; Castagliuolo, I.; Tonus, F.; Gonzalez-Diaz, H. Using the TOPS-MODE approach to fit multi-target QSAR models for tyrosine kinases inhibitors. Eur. J. Med. Chem., 2011, 46, 2185-2192
152. Manetti, F.; Pucci, A.; Magnani, M.; Locatelli, G.A.; Brullo, C.; Naldini, A.; Schenone, S.; Maga, G.; Carraro, F.; Botta, M. Inhibition of Bcr-Abl phosphorylation and induction of apoptosis by pyrazolo[3,4-d]pyrimidines in human leukemia cells. ChemMedChem, 2007, 2, 343-353.
153. Han, L.Y.; Ma, X.H.; Lin, H.H.; Jia, J.; Zhu, F.; Xue, Y.; Li, Z.R.; Cao, Z.W.; Ji, Z.L.; Chen, Y.Z. A support vector machines approach for virtual screening of active compounds of single and multiple mechanisms from large libraries at an improved hit-rate and enrichment factor. J. Mol. Graph. Model., 2008, 26, 1276-1286
154. NCBI-Team. PubChem Database. http://pubchem.ncbi.nlm.nih.gov/citations.html, 2004
155. MDL-Drug Data Report. http://www.symyx.com, 2007.
156. Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov., 2002, 1, 493-502.
157. Muhsin, M.; Graham, J.; Kirkpatrick, P. Gefitinib. Nat. Rev. Drug Discov., 2003, 2, 515-516.
158. Dowell, J.; Minna, J.D.; Kirkpatrick, P. Erlotinib hydrochloride. Nat. Rev. Drug Discov., 2005, 4, 13-14.
159. Tatton, L.; Morley, G.M.; Chopra, R.; Khwaja, A. The Srcselective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases. J. Biol. Chem., 2003, 278, 4847-4853.
160. Warmuth, M.; Simon, N.; Mitina, O.; Mathes, R.; Fabbro, D.; Manley, P.W.; Buchdunger, E.; Forster, K.; Moarefi, I.; Hallek, M. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood, 2003, 101, 664-672.
161. Shah, N.P.; Tran, C.; Lee, F.Y.; Chen, P.; Norris, D.; Sawyers, C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 2004, 305, 399-401.
162. Daub, H.; Specht, K.; Ullrich, A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discov., 2004, 3, 1001-1010.
163. Burchert, A.; Wang, Y.; Cai, D.; von Bubnoff, N.; Paschka, P.; Muller-Brusselbach, S.; Ottmann, O.G.; Duyster, J.; Hochhaus, A.; Neubauer, A. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia, 2005, 19, 1774-1782.
164. Fabbro, D.; McCormick, F. Protein Tyrosine Kinases: From Inhibitors to Useful Drugs, Humana Press: Totowa, New Jersey, 2006.
165. Li, R.; Stafford, J.A. Kinase Inhibitor Drugs, John Wiley & Sons, Inc.: Hoboken, New Jersey, 2009.
166. Todeschini, R.; Consonni, V. Handbook of Molecular Descriptors, WILEY-VCH Verlag GmbH: Weinheim, New York, Chichester, Brisbane, Singapore, Toronto, 2000.
167. Viswanadhan, V.N.; Ghose, A.K.; Revankar, G.R.; Robins, R.K. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J. Chem. Inf. Comput. Sci., 1989, 29, 163-172.
168. Estrada, E.; Patlewicz, G.; Gutierrez, Y. From knowledge generation to knowledge archive. A general strategy using TOPS-MODE with DEREK to formulate new alerts for skin sensitization. J. Chem. Inf. Comput. Sci., 2004, 44, 688-698.
169. Estrada, E.; Uriarte, E.; Gutierrez, Y.; Gonzalez, H. Quantitative structure-toxicity relationships using TOPS-MODE. 3. Structural factors influencing the permeability of commercial solvents through living human skin. SAR QSAR Environ. Res., 2003, 14, 145-163.
170. Estrada, E.; Patlewicz, G.; Chamberlain, M.; Basketter, D.; Larbey, S. Computer-aided knowledge generation for understanding skin sensitization mechanisms: the TOPS-MODE approach. Chem. Res. Toxicol., 2003, 16, 1226-1235.
171. Estrada, E. Spectral moments of the edge adjacency matrix in molecular graphs. 1. Definition and applications for the prediction of physical properties of alkanes. J. Chem. Inf. Comput. Sci., 1996, 36, 844-849.
172. Estrada, E. Spectral moments of the edge adjacency matrix in molecular graphs. 2. Molecules containing heteroatoms and QSAR applications. J. Chem. Inf. Comput. Sci., 1997, 37, 320-328
173. Estrada, E. Spectral moments of the edge adjacency matrix in molecular graphs. 3. Molecules containing cycles. J. Chem. Inf. Comput. Sci., 1998, 38, 23-27.
174. O'Neill, M.J.; Heckelman, P.E.; Koch, C.B.; Roman, K.J. The Merck Index, An Encyclopedia of Chemicals, Drugs and Biologicals, 14th ed.; Whitehouse Station, NJ: Merck & Co., Inc: 2006.
175. Todeschini, R.; Consonni, V.; Mauri, A.; Pavan, M. DRAGON for Windows (Software for Molecular Descriptor Calculations), v5.3; Milano Chemometrics and QSAR Research Group: Milano, 2005
176. Estrada, E.; Gutiérrez, Y. MODESLAB, v1.5; Santiago de Compostela, 2002-2004
177. van de Waterbeemd, H. Chemometrics methods in molecular design, VCH Publishers: Weinheim, New York, Basel, Cambridge, Tokyo, 1995.
178. StatSoft. STATISTICA 6.0. Data analysis software system 2001
179. González-Díaz, H.; Pérez-Bello, A.; Cruz-Monteagudo, M.; González-Díaz, Y.; Santana, L.; Uriarte, E. Chemometrics for QSAR with low sequence homology: Mycobacterial promoter sequences recognition with 2D-RNA entropies. Chemometr. Intell. Lab. Syst., 2007, 85, 20-26.
180. Hanczar, B.; Hua, J.; Sima, C.; Weinstein, J.; Bittner, M.; Dougherty, E.R. Small-sample precision of ROC-related estimates. Bioinformatics, 2010, 26, 822-830.
181. Speck-Planche, A.; Kleandrova, V.V.; Scotti, M.T. Fragment-based approach for the in silico discovery of multi-target insecticides. Chemometr. Intell. Lab. Syst., 2012, 111, 39-45.